Gunjan Shah
@GunjanLShah
Followers
1K
Following
9K
Media
165
Statuses
453
Joined October 2009
Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens. https://t.co/mB0wxmGSQB
@ASCO @JCO_ASCO @JCOOP_ASCO
#FinancialToxicity #ASCOQLTY25
@JoshuaBudhu @fumikochino
0
6
26
This is re(n)ally awesome!!! Well-written guidelines re: kidney transplant in myeloma et al by tour de force team: @vsanchorawala @LandauHeather #nelsonleung et al. Nice figures for #MMsm (stratify by 🐠 & MRD), MGUS, and SMM below. 🚨 MRD-neg *not* needed if standard risk.
Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. - Aim for good disease control in standard-risk myeloma - Aim for MRD negativity in high-risk myeloma - Avoid IMiDs after transplant if possible - Reduce immunosuppression
1
12
40
🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter
https://t.co/k0tQMZBSxS 🧵Let’s break it down
nature.com
Nature Medicine - A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T...
4
42
152
New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use.
mskcc.org
Learn how researchers are making better CAR T cells by taking a lesson from viruses.
1
15
49
Effective cytoreduction in the bridging period can significantly improve outcomes for those planned for CAR T cells - radiotherapy ☢️ is a particularly effective tool for highest risk pts! @CCR_AACR @MSK_RadOnc @CARTTherapy @MSKCancerCenter @ILROGTeam
https://t.co/f2djlgfkrk
pubmed.ncbi.nlm.nih.gov
This is the first study to use radiomics to quantify disease burden pre- and post-BT in a large real-world large B-cell lymphoma cohort. We demonstrate that effective BT can enable initially high-d...
3
7
22
Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea: - Phase 2 trial, 25 pts - 88% improved diarrhea - 68% complete resolution - No effect on lenalidomide PK #mmsm @MSKCancerCenter @MSKHemOncTrials @BloodCancerJnl
https://t.co/KnMOE3tAG0
3
14
56
TCT Community, mark your calendars for one of the most unique conferences of the year. Insightful, practical, & forward-thinking topics focused on improving the tolerability (on all levels) of our therapies https://t.co/44bmo8OUqt
@ASTCT @MSK_DeptOfMed @MSKHemOncTrials
4
7
29
A total cost of care was compared for letermovir prophylaxis versus preemptive therapy. For high-risk pts, letermovir decreases total cost of care through day+180 and for standard-risk pts, letermovir reduces inpatient cost of care through day+180. https://t.co/Okc1Oo8vZs
1
17
58
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. https://t.co/KGCnaQmTqI
#OCENewsBurst
fda.gov
On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and...
0
25
32
Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal
https://t.co/GCMzIIJoDh 1/7
3
11
34
Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉@CIBMTR @nmdp_org @BrianShafferMD @MGooptu @GvHD_Meade @spellman_s @amjimenezmd @DrMonzrAlMalki #PTCyrules
3
13
52
Today marks the 140th anniversary of @MSKCancerCenter founding in 1884 as the New York Cancer Hospital! It was renamed, Memorial Hospital for the Treatment of Cancer and Allied Diseases in 1916. NYC is joining the celebration and @EmpireStateBldg is lit tonight in MSK blue!
0
8
64
Just out: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma. For Limited time: Link to Free copy & more in thread! @TheLancetOncol @YiLinMDPhD @TomBmt133 @szusmani @chngwj @End_myeloma @bdermanmd @mvmateos @jmikhaelmd et al https://t.co/lJwV8yXHST
thelancet.com
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been...
4
45
105